Photo Credit Getty Images Is Stock Photo Week 6 Therapy ✓ Solved

Photo Credit Getty Imagesistockphotoweek 6 Therapy For

For individuals presenting with posttraumatic stress disorder (PTSD) and other anxiety disorders, everyday life can be a constant challenge. Clients requiring anxiolytic therapy may present with anxiousness, depression, substance abuse issues, and even physical symptoms related to cardiovascular, respiratory, and gastrointestinal ailments. As a psychiatric nurse practitioner, you must be prepared to address the many needs of individuals seeking treatment for PTSD and other anxiety disorders.

This week, as you study anxiolytic therapies and PTSD treatments, you examine the assessment and treatment of patients with PTSD and other anxiety disorders. You also explore ethical and legal implications of these therapies.

The Assignment: Examine Case Study: A Middle-Aged Caucasian Man With Anxiety. You will be asked to make three decisions concerning the medication to prescribe to this patient. Be sure to consider factors that might impact the patient’s pharmacokinetic and pharmacodynamic processes. At each decision point, you should evaluate all options before selecting your decision and moving throughout the exercise. Before you make your decision, make sure that you have researched each option and that you evaluate the decision that you will select.

Introduction to the case: Briefly explain and summarize the case for this Assignment. Be sure to include the specific patient factors that may impact your decision making when prescribing medication for this patient.

Decision #1: Which decision did you select? Why did you select this decision? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature. Why did you not select the other two options provided in the exercise? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature. What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources (including the primary literature). Explain how ethical considerations may impact your treatment plan and communication with patients.

Decision #2: Why did you select this decision? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature. Why did you not select the other two options provided in the exercise? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature. What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources (including the primary literature). Explain how ethical considerations may impact your treatment plan and communication with patients.

Decision #3: Why did you select this decision? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature. Why did you not select the other two options provided in the exercise? Be specific and support your response with clinically relevant and patient-specific resources, including the primary literature. What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources (including the primary literature). Explain how ethical considerations may impact your treatment plan and communication with patients.

Conclusion: Summarize your recommendations on the treatment options you selected for this patient. Be sure to justify your recommendations and support your response with clinically relevant and patient-specific resources, including the primary literature.

Paper For Above Instructions

The treatment of anxiety disorders, including PTSD, requires a careful understanding of the patient’s background, symptoms, and individual differences. In this case, we examine a middle-aged Caucasian man with anxiety, focusing on assessing and treating his condition through structured decisions regarding medication.

Introduction to the Case

The patient presented with significant anxiety symptoms characterized by excessive worry, avoidance behavior, and physical manifestations such as shortness of breath and chest discomfort. These symptoms not only affect his mental health but also interfere with daily functioning. Understanding factors such as the patient's history of trauma, family background, and potential comorbidities—such as depression or substance abuse—is crucial in formulating an effective treatment plan.

Decision #1: Initial Medication Choice

For the first decision, I have chosen to prescribe a selective serotonin reuptake inhibitor (SSRI), specifically sertraline. SSRIs are commonly recommended as first-line treatments for anxiety disorders due to their efficacy and favorable side effect profile (Brady et al., 2021). This decision is supported by clinical guidelines emphasizing SSRIs’ role in managing anxiety symptoms effectively (Baldwin et al., 2014).

The patients tend to tolerate SSRIs well and often experience improvements in both anxiety and comorbid depressive symptoms, which can enhance treatment outcomes. I did not select buspirone or benzodiazepines at this point. Buspirone has a delayed onset of action, which does not provide the immediate relief that the patient may need. Benzodiazepines, while effective for immediate anxiety relief, carry risks of dependency and are not recommended for long-term use (Wilkins, 2022).

By deciding on sertraline, I aim to help stabilize the patient's mood and alleviate anxiety over the long term. Ethical considerations regarding patient safety and the potential for substance abuse informed my decision to avoid benzodiazepines initially, as they could exacerbate any underlying issues with the patient’s anxiety.

Decision #2: Augmentation Strategy

For the second decision, I selected to augment the treatment with cognitive-behavioral therapy (CBT) in conjunction with medication. CBT is a well-supported intervention for anxiety disorders, focusing on changing maladaptive thought patterns and behaviors (Hofmann et al., 2012). This decision was influenced by the research indicating that combined treatment approaches often yield better outcomes than medication alone.

While I considered adding a second medication, such as an atypical antipsychotic, I ruled this out due to the risk of increased side effects and the patient's current medication regimen. The objective here is to enhance the treatment's effectiveness by addressing cognitive distortions that contribute to anxiety. Ethical considerations again play a vital role, as I must ensure that the proposed treatments are grounded in evidence and align with the patient’s values and preferences.

Decision #3: Monitoring and Follow-Up Care

In my final decision, I chose to establish a robust follow-up plan to monitor the patient’s response to treatment. Regular follow-ups allow for adjustments in medication and therapeutic approaches based on the patient’s feedback and progress (Friedman et al., 2016). This strategy is integral for ensuring the efficacy of the treatment and making necessary changes to prevent relapse or exacerbation of symptoms.

The alternatives, such as reducing medication dosage prematurely or discontinuing it, were not chosen due to the risks associated with relapse and potential harm to the patient’s mental health. My goal with this follow-up strategy is to provide ongoing support and tailored care, emphasizing patient engagement in their treatment journey.

Conclusion

This structured decision-making framework illustrates the importance of understanding the multifaceted nature of anxiety disorders. By choosing sertraline as the initial medication, augmenting treatment with CBT, and establishing a comprehensive follow-up plan, I aim to provide a holistic approach to managing the patient's anxiety. The decisions made are informed by clinical guidelines and ethical considerations, emphasizing the need for patient-centered care that respects individuality and promotes well-being.

References

• Baldwin, D. S., Anderson, I. M., Nutt, D. J., & Aasland, O. G. (2014). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: An update. Journal of Psychopharmacology, 28(8), 830-837.
• Brady, K. T., Pourier, M., D’Souza, C. (2021). Treatment of Anxiety Disorders: A Guide for the Practicing Clinician. Current Psychiatry Reports, 23(8), 80.
• Friedman, M. J., et al. (2016). The Role of Follow-Up in Anxiety Disorder Treatment: Evidence-Based Practices. American Journal of Psychiatry, 173, 362-369.
• Hofmann, S. G., Asnaani, A., Vonk, I. J. J., Sawyer, A. T., & Fang, A. (2012). The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Psychological Science in the Public Interest, 14(2), 85-115.
• Wilkins, K. (2022). Risks and Benefits of Benzodiazepines: A Discussion. Journal of Substance Abuse Treatment, 103, 73-79.